TL;DR — MCT oil (medium-chain triglycerides, primarily caprylic C8:0 and capric C10:0) is absorbed via the portal vein without micelle formation, delivered directly to hepatocytes, and rapidly β-oxidized to ketones. Human RCTs show ketone elevation (Vandenberghe 2017), improved cognition in mild AD (Cunnane 2020), and modest weight-management effects. Standard dose 10–30 g/day (start low: GI upset is dose-limiting). C8-only ("caprylic") produces the highest ketone response per gram.
What MCT oil does (and why it matters)
Most dietary fat is long-chain triglyceride (LCT, C14+): digested by pancreatic lipase, packaged into chylomicrons, absorbed via lymph, and used mainly for storage or slow oxidation. Medium-chain triglycerides (C6:0–C12:0) — from coconut, palm kernel, and lauric-refined sources — take a shortcut: they bypass micelle formation, cross enterocytes directly, enter the portal vein, and reach the liver within an hour. There they undergo rapid β-oxidation, generating acetyl-CoA → ketone bodies even in the absence of dietary carbohydrate restriction.
For aging, this matters because brain glucose uptake declines ~10% per decade after 40 (Cunnane et al.), while ketone uptake is preserved. Providing an alternative fuel to the brain via MCT-driven ketosis is the mechanism behind the AD-cognition trials.
Primary hallmarks targeted: Mitochondrial dysfunction · Deregulated nutrient sensing · Altered intercellular communication (cerebral fuel)
Vandenberghe et al. (2017, PMID 28633094) — MCT oil dose-response in healthy older adults — 30 g C8 MCT produced 3× the ketone response of coconut oil at the same mass. Cunnane, Fortier, Castellano et al. (2020, PMID 32279606) — 83 mild cognitive impairment adults given kMCT beverage (30 g/day) for 6 months — improved episodic memory, processing speed, and executive function via increased brain ketone uptake shown on PET. Henderson (2009, PMID 19664276) — 152 mild-moderate AD adults — 40 mL/day of AC-1202 (caprylic triglyceride) improved ADAS-Cog at 45 and 90 days.
Mechanism
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| Portal vein absorption | Bypass chylomicron pathway → direct liver uptake | — |
| Hepatic β-oxidation | Rapid oxidation → acetyl-CoA + NADH | Nutrient sensing |
| Ketogenesis | Excess acetyl-CoA → acetoacetate + β-hydroxybutyrate | Nutrient sensing |
| Brain ketone uptake | MCT1/2 transporters unchanged with age; provides alternative fuel | Communication |
| Mitochondrial biogenesis | β-hydroxybutyrate signals via HCAR2, HDAC inhibition | Mitochondrial |
The C8 (caprylic) advantage: pure C8 MCT produces ~3× more ketones per gram than coconut oil (which is only ~7% C8) and 2× more than blended MCT (C8:C10 60:40). If ketone induction is the goal, C8-only formulations are the most efficient.
When MCT oil is worth pursuing
MCT oil earns a place when one or more apply:
- Age 60+ with subjective cognitive decline (target the Cunnane 2020 protocol)
- Time-restricted eating or ketogenic diet, using MCT to smooth ketone dips
- Endurance training with need for rapid fuel that doesn't spike insulin
- Malabsorption syndromes where LCT digestion is impaired
Skip or defer if you have gallbladder disease with severe fat intolerance, insulin-dependent diabetes without CGM support, or a history of pancreatitis.
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Vandenberghe 2017 (PMID 28633094) | Dose-response | 9 | Acute | C8 MCT 3× ketone response vs coconut oil | B |
| Cunnane 2020 (PMID 32279606) | RCT (MCI) | 83 | 6 mo | ↑ Episodic memory, processing speed; ↑ brain ketone uptake on PET | B |
| Henderson 2009 (PMID 19664276) | RCT (AD) | 152 | 90 d | ↑ ADAS-Cog in APOE4-negative subgroup | B |
| Mumme 2015 meta (PMID 25636220) | Meta | 749 | 3–24 wk | Modest weight reduction; small effect | C |
| St-Pierre 2019 (PMID 31088732) | RCT (endurance) | 14 | 2 wk | ↑ Fat oxidation, unchanged performance | C |
← Swipe for more columns →
Consensus: Tier B for MCT-driven ketone elevation and cognitive support in MCI/mild AD. Weight-management effect is real but small (~1–2 kg over 12 weeks vs isocaloric LCT). Longevity outcome data does not exist.
Where MCT oil disappoints
- GI intolerance is dose-limiting. ~30% of users get diarrhea at 30 g. Start at 5 g/day and titrate. - Not a weight-loss magic. The Mumme meta showed ~1–2 kg effect — real but modest, and only when replacing (not adding to) other calories. - Coconut oil is not MCT oil. Coconut oil is ~50% lauric (C12:0), which behaves more like a LCT than a true MCT. Pure MCT products specify C8 and/or C10 content. - APOE4 responders may differ. Henderson 2009 signal was in APOE4-negative subgroup; APOE4 carriers may need different fuels.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Cognitive support (Cunnane) | 30 g/day divided | Titrate from 5 g |
| Metabolic / satiety | 10–20 g/day | Pre-meal for satiety |
| Endurance fuel | 15–30 g pre/mid-workout | Practice in training first |
| Form preference | C8-only for max ketones, C8+C10 for balance | Avoid mixed with lauric |
| Timing | AM or pre-fast for ketone bridge | GI: divide dose |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Blood β-hydroxybutyrate | 0.3–1.5 mmol/L for cognitive protocol | Baseline + weekly first month | Home ketone meter |
| GI tolerance (Bristol stool 3–4) | Normal | Daily first 2 weeks | Reduce dose or split |
| Lipid panel | LDL stable | 3 months | MCT can raise LDL in some (small effect) |
| Weight (if goal) | Trending | Weekly | Not a weight-loss primary tool |
← Swipe for more columns →
Safety, red flags, and contraindications
- Diarrhea + cramping at doses >20 g if untitrated. Common and dose-limiting.
- Rare LDL increase — check lipids at 3 months if using long-term at high doses.
- May trigger ketoacidosis in type 1 diabetes without proper insulin management.
Do not self-start without clearance
- Type 1 diabetes — ketoacidosis risk without CGM/expert management.
- Gallbladder disease with fat intolerance — MCT is better tolerated than LCT but still causes symptoms in some.
- Advanced cirrhosis — impaired hepatic metabolism; discuss with hepatologist.
- Pancreatitis history — high-fat load can precipitate.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Time-restricted eating (16:8+) | Amplifies ketone production; smooths morning ketone dip | Metabolic stack |
| Exogenous ketone salts | Additive ketone elevation for cognitive protocols | Cognitive stack |
| Coffee (bulletproof pattern) | MCT + fasting + caffeine — synergistic fat oxidation | AM protocol |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| High-carbohydrate meals co-timed | Insulin suppresses ketogenesis | Take MCT away from carb meals |
| Coconut oil for MCT purpose | Lauric acid is not MCT-equivalent | Use pure C8/C10 for ketone goal |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.